Umberto Cillo

Padua University Hospital
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2025

Year:

2025

Year:

2025

Background The 2022 Barcelona Clinic Liver Cancer (BCLC) algorithm does not recommend liver resection (LR) in BCLC A patients with oligo-nodular (two or three nodules ≤3 cm) hepatocellular carcinoma (HCC). This sharply contrasts with the therapeutic hierarchy concept, implying a precise treatment order exists within each BCLC stage. This study aimed to compare the outcomes of LR versus radiofrequency ablation (RFA) or trans-arterial chemoembolization (TACE) in BCLC A patients. Methods A meta-analysis adhering to PRISMA guidelines and the Cochrane Handbook was performed. All RCT, cohort and case–control studies that compared LR versus RFA or TACE in oligo-nodular BCLC A HCC published between January 2000 and October 2023 were comprehensively searched on PubMed, Embase, the Cochrane Library and China Biology Medicine databases. Primary outcomes were overall survival (OS) and disease-free survival (DFS) at 3 and 5 years. Risk ratio (RR) was computed as a measure of treatment effect (OS and DFS benefit) to calculate common and random effects estimates for meta-analyses with binary outcome data. Results 2601 patients from 14 included studies were analysed (LR = 1227, RFA = 686, TACE = 688). There was a significant 3- and 5-year OS benefit of LR over TACE (RR = 0.55, 95% c.i. 0.44 to 0.69, P < 0.001 and RR 0.57, 95% c.i. 0.36 to 0.90, P = 0.030, respectively), while there was no significant 3- and 5-year OS benefit of LR over RFA (RR = 0.78, 95% c.i. 0.37 to 1.62, P = 0.452 and RR 0.74, 95% c.i. 0.50 to 1.09, P = 0.103, respectively). However, a significant 3- and 5-year DFS benefit of LR over RFA was found (RR = 0.70, 95% c.i. 0.54 to 0.93, P = 0.020 and RR 0.82, 95% c.i. 0.72 to 0.95, P = 0.015, respectively). A single study comparing LR and TACE regarding DFS showed a significant superiority of LR. The Newcastle–Ottawa Scale quality of studies was high in eight (57%) and moderate in six (43%). Conclusions In BCLC A oligo-nodular HCC patients, LR should be preferred to RFA or TACE (therapeutic hierarchy concept). Additional comparative cohort studies are urgently needed to increase the certainty of this evidence.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2021

Collaborators (10)

FEDERICO NALESSO

Professore Associato

University of Padova

ITALY
View details

Alessandro Vitale

University of Padua

ITALY
View details

Timothy M. Pawlik

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Jacopo Lanari

Assistant Professor in General Surgery

University of Padua

ITALY
View details

Lorenzo A. Calò

University of Padua

ITALY
View details

Maria Reig

Head of the Liver Oncology group-CIBER

-

SPAIN
View details

PIETRO ANDREONE

Professor of Medicine and Surgery

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia

ITALY
View details

FRANCESCO ENRICO D'AMICO

Professore Associato

Università degli studi di Padova Scuola di Scienze

ITALY
View details

Patrizia Burra

Full Professor in Gastroenterology

University of Padova

ITALY
View details

Alberto Ferrarese

Padua University Hospital

ITALY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.